Laura Manca

  1. Going mobile - making healthcare more patient focused

    Mobile has revolutionised everyday life and now big pharma is using smartphones and other mobile devices to improve research and development.

    Mobile phone with TheSocialMedwork service being used 

    完整阅读 »
  2. Ovarian cancer

    A personalised vaccine which boosts a patient’s own immune system has nearly doubled the number of women surviving ovarian cancer by two years.

    ovarian cancer

    完整阅读 »
  3. Lung cancer

    Following an earlier negative decision, NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.

    lung cancer

    完整阅读 »
  4. Ovarian cancer

    Rubraca (rucaparib), already approved as a treatment for BRCA positive ovarian cancer, has been approved as a maintenance therapy for ovarian cancer regardless of BRCA mutation. 
    Industry news

    完整阅读 »
  5. Leukemia

    The FDA approves Blincyto (blinatumomab) for patients with B-cell ALL, who are in remission but still have minimal residual disease.
    leukemia

    完整阅读 »
  6. Pediatric leukemia

    FDA approves Tasigna (nilotinib) for certain pediatric patients with Ph+ CML in chronic phase.
    Industry news

    完整阅读 »
  7. Diabetic retinopathy

    FDA approves Genentech’s Lucentis (ranibizumab injection) syringe for diabetic macular edema and diabetic retinopathy.

    FDA

    完整阅读 »
  8. Leukemia

    CLL expert explains latest treatment developments in the field.
    leukemia

    完整阅读 »
  9. Lymphoma

    FDA expands approval of Adcetris (brentuximab vedotin) for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.
    Industry news

    完整阅读 »
  10. Prostate cancer

    Expert emphasises healthy lifestyle in prostate cancer care.
    Industry news

    完整阅读 »
Posts loader